JP2016529223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529223A5 JP2016529223A5 JP2016523852A JP2016523852A JP2016529223A5 JP 2016529223 A5 JP2016529223 A5 JP 2016529223A5 JP 2016523852 A JP2016523852 A JP 2016523852A JP 2016523852 A JP2016523852 A JP 2016523852A JP 2016529223 A5 JP2016529223 A5 JP 2016529223A5
- Authority
- JP
- Japan
- Prior art keywords
- rv1733c
- mtb
- rv2626c
- mtb antigen
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 101100103958 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv1733c gene Proteins 0.000 claims 13
- 239000013598 vector Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 241001217856 Chimpanzee adenovirus Species 0.000 claims 9
- 101100395578 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hrp1 gene Proteins 0.000 claims 9
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims 4
- -1 ESAT6 Proteins 0.000 claims 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 4
- 101100156500 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) vapB47 gene Proteins 0.000 claims 4
- 101150053438 PPE51 gene Proteins 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 241001135569 Human adenovirus 5 Species 0.000 claims 3
- 241001135572 Human adenovirus E4 Species 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 3
- 208000007089 vaccinia Diseases 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 101100445609 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) espC gene Proteins 0.000 claims 2
- 101150082852 PPE15 gene Proteins 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 101150014428 mpt64 gene Proteins 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838872P | 2013-06-25 | 2013-06-25 | |
| US61/838,872 | 2013-06-25 | ||
| PCT/US2014/043889 WO2014210018A1 (en) | 2013-06-25 | 2014-06-24 | Tuberculosis compositions and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019124873A Division JP7269806B2 (ja) | 2013-06-25 | 2019-07-04 | 結核組成物及びそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529223A JP2016529223A (ja) | 2016-09-23 |
| JP2016529223A5 true JP2016529223A5 (enExample) | 2017-08-03 |
| JP6554095B2 JP6554095B2 (ja) | 2019-07-31 |
Family
ID=52111114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523852A Active JP6554095B2 (ja) | 2013-06-25 | 2014-06-24 | 結核組成物及びそれを使用する方法 |
| JP2019124873A Active JP7269806B2 (ja) | 2013-06-25 | 2019-07-04 | 結核組成物及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019124873A Active JP7269806B2 (ja) | 2013-06-25 | 2019-07-04 | 結核組成物及びそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10266574B2 (enExample) |
| EP (2) | EP3013364B1 (enExample) |
| JP (2) | JP6554095B2 (enExample) |
| CN (1) | CN105431166B (enExample) |
| ES (1) | ES2925950T3 (enExample) |
| WO (1) | WO2014210018A1 (enExample) |
| ZA (1) | ZA201509262B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357555B2 (en) * | 2012-07-10 | 2019-07-23 | Transgene Sa | Mycobacterial antigen vaccine |
| EP3013364B1 (en) | 2013-06-25 | 2022-08-03 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
| RU2695462C2 (ru) * | 2014-01-09 | 2019-07-23 | Трансген Са | Гибридизация гетероолигомерных микобактериальных антигенов |
| WO2016120489A2 (en) * | 2015-02-01 | 2016-08-04 | Theravectys | Lentiviral vectors for expression of mycobacterium tuberculosis antigens |
| WO2017218867A1 (en) * | 2016-06-16 | 2017-12-21 | Aeras | Tuberculosis compositions and methods of treating or preventing tuberculosis |
| EP3474889A4 (en) * | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES |
| EP3555630B1 (en) | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| CN108239660B (zh) * | 2016-12-26 | 2021-08-10 | 上海生物制品研究所有限责任公司 | 一种重组结核病疫苗，其制备方法及应用 |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
| KR102135334B1 (ko) * | 2018-12-19 | 2020-07-17 | 대한민국 | 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물 |
| CN116327906A (zh) * | 2021-12-22 | 2023-06-27 | 中国人民解放军总医院第八医学中心 | 一种结核分枝杆菌串联dna疫苗w545及其制备方法与应用 |
| CN117777259B (zh) * | 2024-02-23 | 2024-06-07 | 上海科新生物技术股份有限公司 | 检测结核感染的抗原组合物、试剂盒及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| PT681483E (pt) | 1993-01-26 | 2005-11-30 | Wyeth Corp | Composicoes e metodos para distribuicao de material genetico |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| CN101198358B (zh) | 2004-12-01 | 2013-06-26 | Aeras全球Tb疫苗基金会 | 具有增强的逃出内体能力的重组bcg菌株 |
| AU2006261445B2 (en) | 2005-06-23 | 2011-03-31 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| US20090304750A1 (en) * | 2005-12-15 | 2009-12-10 | David Hone | Novel prime-boost combinations of attenuated mycobacterium |
| MX2009010800A (es) * | 2007-04-04 | 2010-01-29 | Infectious Disease Res Inst Id | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
| US7670609B2 (en) * | 2007-11-27 | 2010-03-02 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease |
| US8361482B2 (en) | 2007-11-27 | 2013-01-29 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease |
| CN101289496B (zh) | 2008-05-30 | 2011-06-29 | 中国医学科学院医学生物学研究所 | 能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途 |
| WO2010129339A2 (en) * | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| GB0918154D0 (en) * | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| BR112012003380A2 (pt) * | 2009-11-02 | 2016-11-16 | Biocomo Co Ltd | vacina contra tuberculose do tipo spray intranasal usando um vetor de paramyxovírus. |
| PL2528621T3 (pl) | 2010-01-27 | 2017-07-31 | Glaxosmithkline Biologicals S.A. | Zmodyfikowane antygeny gruźlicy |
| US20120003256A1 (en) | 2010-03-01 | 2012-01-05 | Huiling Han | Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same |
| GB201008512D0 (en) * | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| US10357555B2 (en) * | 2012-07-10 | 2019-07-23 | Transgene Sa | Mycobacterial antigen vaccine |
| EP3013364B1 (en) | 2013-06-25 | 2022-08-03 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
| CN104474538A (zh) | 2014-08-13 | 2015-04-01 | 华中科技大学 | 一种重组卡介苗 |
-
2014
- 2014-06-24 EP EP14817274.5A patent/EP3013364B1/en active Active
- 2014-06-24 WO PCT/US2014/043889 patent/WO2014210018A1/en not_active Ceased
- 2014-06-24 JP JP2016523852A patent/JP6554095B2/ja active Active
- 2014-06-24 EP EP22188098.2A patent/EP4176897A1/en active Pending
- 2014-06-24 ES ES14817274T patent/ES2925950T3/es active Active
- 2014-06-24 US US14/313,694 patent/US10266574B2/en active Active
- 2014-06-24 CN CN201480040735.5A patent/CN105431166B/zh active Active
-
2015
- 2015-12-18 ZA ZA2015/09262A patent/ZA201509262B/en unknown
-
2019
- 2019-03-01 US US16/289,919 patent/US11014969B2/en active Active
- 2019-07-04 JP JP2019124873A patent/JP7269806B2/ja active Active
-
2021
- 2021-04-21 US US17/236,409 patent/US11787842B2/en active Active
-
2023
- 2023-09-06 US US18/461,754 patent/US20240101612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529223A5 (enExample) | ||
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2015533841A5 (enExample) | ||
| WO2015054653A3 (en) | Methods of predicting ancestral virus sequences and uses thereof | |
| HK1254848A1 (zh) | 祖先病毒序列及其应用 | |
| JP2015081257A5 (enExample) | ||
| WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
| JP2017505605A5 (enExample) | ||
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| JP2014530010A5 (enExample) | ||
| WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
| EA201590304A1 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса | |
| WO2016176624A3 (en) | Porcine pestvirus, vaccines, and assays | |
| WO2014063704A8 (en) | M. tuberculosis vaccines | |
| WO2012021730A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| JP2017528075A5 (enExample) | ||
| WO2012048817A3 (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| JP2015188307A5 (enExample) | ||
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| Garg et al. | Development of novel carrier (s) mediated tuberculosis vaccine: more than a tour de force | |
| EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| DK3016673T3 (da) | Pattedyrsmælkeosteopontin til forbedring af immunreaktion | |
| JP2017529355A5 (enExample) | ||
| JP2019532635A5 (enExample) | ||
| EP3054013A4 (en) | IMMUNOGENOUS FORMULATION WITH RECOMBINANT LIVE BCG FOR THE EXPRESSION OF ANTIGENES OF METAPNEUMOVIRUS (HMPV) IN A SUSPENSION MADE FROM A LYOPHILISATE WITHOUT THE NEED FOR A PHARMACEUTICAL USE AGENT |